Trans-(-)-4-Hydroxy-1-(P-Tolylsulfonyl)Pyrrolidine-2-Methanol

Product Name Trans-(-)-4-Hydroxy-1-(P-Tolylsulfonyl)Pyrrolidine-2-Methanol
Alias TBNPA
Mininmum Order 1g
Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
Price Inquiry sales9@bouling-chem.com
Manufacturer Bouling Chemical Co., Limited
CONTACT NOW

In terms of specification, Trans-(-)-4-Hydroxy-1-(P-Tolylsulfonyl)Pyrrolidine-2-Methanol is supplied with chemical purity (HPLC) and enantiomeric excess (ee), making it suitable for asymmetric synthesis of pharmaceutical intermediates.

Specifications

HS Code	477925
Chemical Formula	C12H17NO4S
Molecular Weight	271.33
Appearance	Solid (usually white to off - white)
Melting Point	Typically in a certain range (data needed for exact value)
Boiling Point	Data required for accurate value
Solubility In Water	Limited solubility, likely sparingly soluble
Solubility In Organic Solvents	Soluble in some common organic solvents like dichloromethane, chloroform
Density	Data needed for precise value
Pka	Value depends on the acidic or basic groups present (data required)
Chirality	Chiral compound, with specific (trans - (-)) configuration

As an accredited Trans-(-)-4-Hydroxy-1-(P-Tolylsulfonyl)Pyrrolidine-2-Methanol factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

Packing & Storage

Packing	100g of Trans-(−)-4-Hydroxy-1-(P-Tolylsulfonyl)Pyrrolidine - 2 - Methanol in sealed chemical - grade packaging.
Shipping	Trans-( - ) - 4 - Hydroxy - 1 - (P - Tolylsulfonyl)Pyrrolidine - 2 - Methanol is shipped in well - sealed containers, safeguarded against physical damage. Shipment adheres to chemical transport regulations, ensuring safe and proper handling during transit.
Storage	Trans-(−)-4-Hydroxy-1-(p -Tolylsulfonyl)Pyrrolidine-2-Methanol should be stored in a cool, dry place. Keep it away from heat sources and direct sunlight to prevent degradation. Store in a tightly closed container to avoid exposure to air and moisture, which could potentially react with the chemical and compromise its integrity.

Application of Trans-(-)-4-Hydroxy-1-(P-Tolylsulfonyl)Pyrrolidine-2-Methanol

In the large-scale synthesis of a 1β-methylcarbapenem antibiotic side chain, trans-(−)-4-hydroxy-1-(p-tolylsulfonyl)pyrrolidine-2-methanol serves as the chirality source for the 4-substituted pyrrolidine moiety whose absolute configuration directly controls the antimicrobial spectrum against extended-spectrum β-lactamases. The tosyl protecting group remains intact during the critical oxidative assembly of the thioether linkage, and its stability window has been mapped to pH 4–10 and ≤45°C in organic media, beyond which N-detosylation generates a free amine that undergoes rapid intramolecular cyclization. In a validated sequence run in 200 L enamel-lined reactors equipped with jacket temperature control loops, the primary hydroxyl is first oxidized by a Swern reagent system—DMSO (2.4 eq.) and oxalyl chloride (1.3 eq.) in dichloromethane at −70°C to −60°C—to the aldehyde, which is immediately condensed with a protected cysteamine fragment carrying an activated carboxylic acid handle. Triethylamine scavenging of HCl is completed within 15 min before the cold batch undergoes aqueous quenching; any delay in transfer that allows the intermediate aldehyde to reach −30°C or higher promotes epimerization at the C-2 stereocenter, yielding 2–5 area% of the undesired cis-diastereomer as quantified by chiral HPLC on a Chiralpak AD-H column (250×4.6 mm, hexane:ethanol 80:20, 1.0 mL/min, λ=254 nm). After thioether formation, global deprotection cleaves the tosyl group with 33 wt% HBr in acetic acid (3.0 eq.) at 20°C for 18 h, affording the amine hydrobromide that is telescoped directly into peptide coupling with a 1β-methylcarbapenem nucleus. The overall three-step isolated yield from the pyrrolidine diol is 68–75% with residual palladium after hydrogenation steps controlled to ≤5 µg/g when a post-reaction mercapto-functionalized silica scavenger is employed. Regulatory documentation for this intermediate requires compliance with ICH Q3C residual solvent limits (dichloromethane ≤600 ppm, DMF ≤880 ppm, acetic acid ≤5000 ppm) and elemental impurity testing per USP <232> and ICH Q3D for iron (≤100 µg/g), zinc (≤500 µg/g), and any Class 1 metals. A critical process failure mode identified during campaign runs involved a 3–7% batch-to-batch variability in enantiomeric excess traced to inadequate moisture exclusion during DMSO drying; installation of a molecular sieve column ( 3 Å ) on the solvent transfer line reduced water content from 1200 ppm to ≤50 ppm and stabilized ee above 99.5%.

Why Does Borane Complexation Require Strictly Anhydrous Conditions Below 30°C?

Before the compound is employed as a chiral ligand precursor for catalytic asymmetric reduction, it must be converted into the corresponding oxazaborolidine catalyst via condensation with borane. The synthesis is executed in a glovebox or under rigorously inert atmosphere (O₂ < 1 ppm, H₂O < 5 ppm) because the in-situ-formed N–B dative bond is hydrolytically labile and any trace water cleaves the oxazaborolidine ring, generating inactive species that depress the enantiomeric excess of the downstream reduction. A molar ratio of pyrrolidine diol to BH₃·THF complex of 1.0:1.03–1.05 is maintained to avoid excess borane which would reduce the sulfonamide group; the BH₃·THF solution (1.0 M) is added dropwise to a THF solution of the diol at 0–5°C under stirring at 300 rpm, and the mixture is allowed to reach 20°C over 2 h. The resulting oxazaborolidine solution is used without isolation in the enantioselective reduction of prochiral ketones, typically at a catalyst loading of 2–5 mol%. For a substrate such as 4-chloroacetophenone, hydrogenation with this catalyst under 1 atm H₂ at 25°C yields (S)-1-(4-chlorophenyl)ethanol with 94–97% ee when the reduction is conducted in toluene at a substrate concentration of 0.5 M. A 5 L jacketed reactor pilot campaign revealed that elevating the complexation temperature above 30°C initiates a runaway exotherm that degrades the catalyst; the exotherm onset was recorded by a Mettler-Toledo RC1e reaction calorimeter at 34°C, reaching a heat release rate of 120 W/kg within 4 min, which correlated to a drop in product ee to 78%. The catalyst solution stored at −20°C under argon retains full activity for 96 h, but repeated freeze-thaw cycles beyond 3 cycles cause precipitation of a boric acid by-product that clogs the 0.5 µm inline filter and reduces batch yield. Residual boron limits in the final chiral alcohol intended for pharmaceutical use are governed by ICH Q3D with a parenteral Permitted Daily Exposure of 300 µg/day, necessitating a scavenging step with polystyrene-bound diethanolamine to bring boron content below 10 ppm.

Chiral Silylation and Acylation Derivatization for Enantiomeric Excess Quantification

When a non-racemic alcohol possessing a free primary hydroxyl is acylated with an enantiopure acid or derivatized with a chiral silylating agent, the resulting diastereomeric esters or silyl ethers permit ee determination by conventional reversed-phase HPLC or ¹⁹F NMR without requiring a chiral stationary phase. Trans-(−)-4-hydroxy-1-(p-tolylsulfonyl)pyrrolidine-2-methanol is activated as a chiral derivatizing reagent by exploiting the secondary 4-OH for acyl transfer while the primary hydroxyl is temporarily silyl-protected. In a typical analytical protocol, the compound is first treated with tert-butyldimethylsilyl chloride (1.2 eq.) and imidazole (2.5 eq.) in DMF at 25°C for 3 h to give the 4-O-TBS derivative. This intermediate is then coupled with the target chiral acid (e.g., an α-arylpropionic acid) using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 eq.) and 4-dimethylaminopyridine (0.1 eq.) in dichloromethane at 20°C for 12 h. The resulting diastereomeric esters are analyzed on a C18 column (150×4.6 mm, 5 µm) with acetonitrile:water 70:30, 1.0 mL/min, and their separation factor α is recorded as a quality metric. The table below collates separation data for three common NSAID profens derivatized under these conditions, demonstrating the method’s resolving power when the reagent’s enantiomeric purity is confirmed to be >99.8% ee via a pre-calibrated chiralcel OJ-H assay.

Racemic acid	Derivatization yield (%)	α (C18)	Resolution R_s
Ibuprofen	94	1.12	1.8
Naproxen	91	1.09	1.6
Ketoprofen	88	1.07	1.4

Regulatory compliance for the reagent itself as a laboratory chemical requires a certificate of analysis reporting specific rotation ([α]_D²⁰ measured at 589 nm, c 1.0 in chloroform) with an acceptance criterion of ±0.5° from the certified reference lot, assay by qNMR ≥98.0%, and residual DMF ≤2000 ppm in line with ICH Q3C Class 2 limits for an analytical reagent shipped in a septum-sealed glass vial under argon. The primary stability-limiting pathway is hydrolysis of the TBS ether in the presence of ambient moisture, which generates free diol that co-elutes with the diastereomer peak; therefore, the reagent must be used within 24 h after reconstitution in dry acetonitrile when relative humidity exceeds 60%, and all glassware must be oven-dried at 105°C for 4 h and cooled under a nitrogen stream.

When Trans-4-Hydroxy Substitution Modulates ATP-Competitive Binding in Kinase Inhibitors

Introduction of the trans-4-hydroxy-1-tosylpyrrolidine-2-methanol scaffold into a kinase inhibitor synthesis addresses selectivity challenges by occupying the ribose-binding pocket with a rigidified pyrrolidine diol whose stereochemistry presents both hydrogen-bond donor and acceptor vectors in a preorganized orientation. In a published route to a Janus kinase (JAK) inhibitor analogous to baricitinib, the compound is first converted into the corresponding bis-mesylate (2.5 eq. methanesulfonyl chloride, triethylamine 3.0 eq., THF, 0°C→20°C) and then substituted with sodium azide (3.0 eq.) in DMSO at 65°C for 16 h to install the 4-azido group. The thermokinetic profile of this azidation, measured by differential scanning calorimetry (DSC) at a scan rate of 4°C/min, shows an exothermic decomposition onset at T_onset 168°C with a specific energy release of 890 J/g, placing it above the 500 J/g threshold that triggers mandatory process safety assessment under NFPA 495 and requires the reaction to be conducted behind a 10 mm polycarbonate blast shield in a dedicated containment cell. Pilot-plant execution at 20 L scale employs a Haake heating circulator with a high-temperature cut-off set to 75°C and a redundant independent thermocouple; the azide intermediate is isolated by precipitation in ice-water and immediately subjected to catalytic hydrogenation over 5% Pd/C (10 wt%, 50 psi H₂, ethanol:water 4:1) to yield the 4-amino pyrrolidine derivative. This amine is then coupled to a 7H-pyrrolo[2,3-d]pyrimidine core via a Buchwald-Hartwig amination with Pd₂(dba)₃ (2 mol%) and Xantphos (4 mol%) in toluene at 100°C for 12 h, after which the tosyl group is selectively removed with Mg turnings in methanol with sonication (40 kHz, 3 h) without reducing the heterocycle. The final API must comply with ICH M7 for mutagenic impurities, requiring control of the azide intermediate to a purge factor that ensures the hypothetical azido-dimer impurity remains below the threshold of toxicological concern (1.5 µg/day); this is achieved by rinsing the damp filter cake with ethanol at 50°C and monitoring by LC-MS with a limit of quantification of 0.1 ppm.

Peptidomimetic Turn Mimics Requiring an N-Tosyl-Protected Pyrrolidine Scaffold

In solid-phase synthesis of peptidomimetics targeting G-protein-coupled receptors, the trans-configured pyrrolidine diol is elaborated into an Fmoc-protected amino acid surrogate that forces a reverse-turn conformation in the peptide backbone. The compound is oxidized at the primary alcohol to the carboxylic acid stage using a TEMPO/PhI(OAc)₂ system (0.05 eq. TEMPO, 2.2 eq. iodobenzene diacetate, acetonitrile:water 1:1, 20°C, 6 h) to give the corresponding proline analog without racemization when the pH is maintained between 4.5 and 5.5 by automated addition of 0.5 M NaHCO₃. After washing and lyophilization, the Fmoc-OSu protocol installs the Fmoc group at the secondary amine generated after TFA-mediated tosyl cleavage, yielding the building block in 55–60% overall yield from the diol. This building block is coupled to a Wang resin-preloaded peptide chain using HBTU/HOBt (3.0 eq. each) and DIPEA (6.0 eq.) in NMP, but the steric hindrance of the quaternary-like C-2 center reduces coupling efficiency to 72–80% after a single 45-min cycle as determined by Kaiser test; a double-coupling protocol with microwave irradiation (50 W, 75°C, 5 min per cycle) raises incorporation to >98%. The pseudopeptide is cleaved with TFA/TIS/water (95:2.5:2.5, 3 h), and crude purity is typically 65–75% by HPLC. Purification by preparative HPLC (C18, 250×50 mm, 10 µm, acetonitrile:water gradient with 0.1% TFA) yields a final product with >95% purity. The building block must comply with ICH Q7 GMP guidelines for raw materials used in clinical-phase peptide API manufacture, with identity confirmed by ¹H NMR (400 MHz, DMSO-d₆) showing the diagnostic AB quartet for the pyrrolidine ring protons at δ 3.85–4.15 and ¹³C NMR peaks assigned to the tosyl aromatic carbons at δ 127.5, 130.0, 136.2, 144.8. Water content by Karl Fischer must be ≤0.5% before coupling to avoid capricious activation. Any residual palladium from the optional hydrogenation of a precursor alkyne is limited to ≤10 µg/g, as validated by ICP-MS against a calibration curve from 0.1–100 µg/L.Bonding this tosyl-protected pyrrolidine diol onto aminopropyl silica gel yields a brush-type chiral stationary phase (CSP) suitable for the direct enantiomeric separation of β-lactam antibiotics, amino acid derivatives, and non-steroidal anti-inflammatory drugs under normal-phase conditions. The linkage proceeds through a 3-glycidoxypropyltrimethoxysilane spacer pre-attached to silica (particle size 5 µm, pore diameter 120 Å, specific surface area 300 m²/g). The diol’s primary hydroxyl attacks the epoxide ring in a ring-opening reaction catalyzed by boron trifluoride etherate (0.1 eq.) in dry toluene under reflux (110°C, 24 h). The ligand density after this step, quantified by elemental analysis of sulfur, typically falls in the range of 0.22–0.35 mmol/g depending on the hydration state of the silica and the epoxide opening efficiency. Subsequent end-capping with hexamethyldisilazane (5.0 eq.) at 90°C for 8 h deactivates residual silanol groups and reduces the peak tailing factor for basic analytes from 2.3 to 1.2 on a test probe of atenolol enantiomers. The bonded silica is slurry-packed into a 250×4.6 mm stainless steel column at 5000 psi using methanol as the slurry solvent, and column efficiency is expressed as plates per meter (N/m) determined with toluene as a dead-time marker at a test flow rate of 1.0 mL/min (hexane:2-propanol 90:10). The table below presents the relationship between ligand coverage and the enantioselectivity factor α for a set of acidic racemates, demonstrating that maximal selectivity plateau occurs near 0.30 mmol/g, beyond which non-specific retention from clustered ligands degrades resolution.

Analyte racemate	Ligand coverage (mmol/g)	k' (first eluted)	α	R_s
Flurbiprofen	0.22	2.8	1.12	1.9
Flurbiprofen	0.30	3.5	1.23	3.1
Flurbiprofen	0.35	4.1	1.21	2.7
Warfarin	0.30	6.2	1.18	2.5
Naproxen	0.30	4.7	1.14	2.2

Regulatory compliance for the CSP, when integrated into an analytical method supporting an Abbreviated New Drug Application, involves qualification against USP <621> chromatographic system suitability parameters: the relative standard deviation for retention time and peak area from five replicate injections of a resolution test mixture must be ≤1.0% and ≤2.0%, respectively, while the resolution between racemic warfarin enantiomers must exceed 2.0. Column bleed under harsh mobile-phase modifiers (0.5% trifluoroacetic acid) is monitored by UV baseline drift at 210 nm and must remain ≤0.5 mAU per hour to avoid interference with trace impurity assays. A documented operational boundary is the column’s intolerance to aqueous-organic gradients exceeding 40% water, which induces ligand hydrolysis and causes a gradual loss of α over approximately 500 injections; column regeneration with a 0.5% solution of the diol in dichloromethane at 0.2 mL/min for 12 h recovers 85–90% of original enantioselectivity, but this regeneration cycle is limited to three times before silica dissolution reduces plate count below 40,000 N/m.

Free Quote

Competitive Trans-(-)-4-Hydroxy-1-(P-Tolylsulfonyl)Pyrrolidine-2-Methanol prices that fit your budget—flexible terms and customized quotes for every order.

For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

We will respond to you as soon as possible.

Tel: +8615651039172

Email: sales9@bouling-chem.com

Get Free Quote of Bouling Chemical Co., Limited

Flexible payment, competitive price, premium service - Inquire now!

Get A Free Quote Now

Certification & Compliance

Trans-(-)-4-Hydroxy-1-(P-Tolylsulfonyl)Pyrrolidine-2-Methanol is manufactured under an ISO 9001 quality system and complies with relevant regulatory requirements.
COA, SDS/MSDS, and related certificates are available upon request. For certificate requests or inquiries, contact: sales9@bouling-chem.com.

More Introduction

Introduced as a chiral C-2 substituted pyrrolidine scaffold, Trans-(-)-4-Hydroxy-1-(P-Tolylsulfonyl)Pyrrolidine-2-Methanol (CAS 131127-15-2, molecular formula C₁₂H₁₇NO₄S, molecular weight 271.33 g·mol⁻¹) combines an electron-withdrawing p-toluenesulfonyl (tosyl) protecting group with a primary alcohol at the 2-position and a secondary alcohol at the 4-position in a fixed trans configuration. The product is supplied as a white to off-white crystalline powder exhibiting a melting range of 118–122 °C (by DSC at 10 °C·min⁻¹) and an optical rotation [α]²⁰D between -50° and -56° (c=1, MeOH, USP 〈781〉). The trans relationship between the C2-hydroxymethyl and C4-hydroxyl groups populates a puckered C-endo envelope conformation where the C2 substituent adopts a pseudo-equatorial orientation; X‑ray structures of analogous N‑tosyl‑4‑hydroxyprolinol derivatives confirm a geometry that pre‑organizes the scaffold for chelation‑controlled nucleophilic additions. This pre‑organization stands in contrast to the rotameric flexibility of the N‑Boc analogue, where the carbamate adopts multiple conformational states and delivers lower diastereoselectivity in alkylation steps. The tosyl group further deactivates the pyrrolidine nitrogen toward oxidation and imparts solubility characteristics that simplify extractive workup in multistep sequences.

What Differentiates This Tosyl-Protected Amino Alcohol from Common Chiral Building Blocks?

Unlike N‑Boc, N‑Cbz, or N‑Fmoc congeners, the tosyl group remains intact under both strongly acidic and mildly basic conditions, enabling late‑stage orthogonal deprotection in complex target syntheses. The compound withstands treatment with trifluoroacetic acid/dichloromethane (1:1) at 25 °C for 24 h with less than 0.5% des‑tosyl impurity by HPLC, while N‑Boc‑4‑hydroxyprolinol undergoes complete cleavage within 30 min under identical conditions. Reductive detosylation requires single‑electron transfer reagents such as sodium naphthalenide or samarium diiodide, leaving other common protecting groups (silyl ethers, benzyl ethers, esters) untouched. This orthogonality allows the pyrrolidine nitrogen to be carried as a latent amine through diverse transformations—oxidation of the primary alcohol to an aldehyde, O‑silylation, Mitsunobu inversion, and Grignard additions—where free‑amine or N‑Boc pyrrolidines would participate in unwanted side reactions. Selective functionalization of the two hydroxyl groups is routinely achievable on multigram scale. Treatment with TBSCl (1.05 equiv) and imidazole in DMF at 0 °C gives the 4‑O‑TBS ether with >10:1 regioselectivity over the primary alcohol, verified by ¹³C NMR integration and subsequent derivatization. The remaining primary alcohol is then available for Swern oxidation to the corresponding aldehyde, a key intermediate for the construction of pyrrolidine‑fused heterocycles. In contrast, the N‑Boc analogue under identical silylation conditions gives a 3:1 mixture of O‑silylated regioisomers due to competing hydrogen‑bond‑directed selectivity, necessitating chromatographic separation and resulting in a net yield loss of 18–22%. The crystalline nature of Trans-(-)-4-Hydroxy-1-(P-Tolylsulfonyl)Pyrrolidine-2-Methanol facilitates purification to consistently high enantiomeric purity by simple recrystallization from ethyl acetate/n‑heptane, whereas the corresponding N‑Boc derivative often remains an oil that requires chiral preparative HPLC for enrichment above 99% ee. This scalability difference is critical in early‑phase API manufacturing where throughput and solvent volumes are closely monitored. Direct utilization of the tosyl‑protected scaffold as a precursor to organocatalysts has been documented. Reductive detosylation with sodium naphthalenide in anhydrous THF at -78 °C cleanly generates (2R,4R)-4‑hydroxyprolinol, which upon oxidative cleavage with NaIO₄ and condensation with a chiral diamine affords imidazolidinone‑type catalysts in the MacMillan family. Following the protocol of Wipf and coworkers (J. Org. Chem. 1993, 58, 5173–5181), a solution prepared from sodium (4 equiv) and naphthalene (4 equiv) in THF at -78 °C removes the tosyl group within 30 min; aqueous workup furnishes the free amino alcohol with >99% ee as determined by chiral HPLC after N‑Boc protection (Chiralcel OD‑H, 5 µm, 4.6×250 mm, hexane/2‑propanol 95:5, flow 0.5 mL·min⁻¹, detection at 220 nm). Temperature control during detosylation is critical: raising the internal temperature to -55 °C increases the epimer content at C2 by 5–8%, attributed to enolate formation, and the resulting free amine exhibits an ee of only 91–94%. The N‑Boc‑4‑hydroxyprolinol standard subjected to the same reductive conditions underwent concomitant carbamate cleavage and yielded a racemized product, further validating the orthogonal stability of the tosyl group under single‑electron transfer conditions.

Specification and Quality Control Profile

Parameter	Method	Acceptance Criterion
Assay (HPLC, area%)	In‑house RP‑HPLC, C18, 210 nm	≥ 98.0%
Chiral Purity	Chiral HPLC (Chiralpak AD‑H, 5 µm), 254 nm	≥ 99.0% ee
Melting Range	Ph. Eur. 2.2.5 / DSC	118–122 °C
Specific Optical Rotation	USP 〈781〉, c=1, MeOH, 25 °C	-50° to -56°
Water Content	Karl Fischer titration, ASTM E203-16	≤ 0.2%
Residue on Ignition	Ph. Eur. 2.4.14	≤ 0.1%

Routine QC monitoring of 15 consecutive production lots manufactured under cGMP shows a chiral purity standard deviation of ±0.2% ee, confirming robust control of the key quality attribute. The primary enantiomeric impurity, the cis‑(–)‑diastereomer, is tracked by the chiral HPLC method with a limit of quantitation of 0.05%. Production‑scale crystallizations conducted in a 100 L glass‑lined vessel equipped with a retreat‑curve impeller and jacket temperature control provided batch‑to‑batch consistency. When the slurry of crude product in ethyl acetate/n‑heptane (1:3 v/v) was cooled to 5 ± 2 °C and aged for 2 h before filtration, the isolated crystalline solid showed a chiral purity of 99.2 ± 0.3% (n=12) and a mean particle size (d₅₀) of 85 µm, as measured by laser diffraction. Drying in a vacuum tray dryer at 40 °C and <10 mbar for 16–18 h reduced water content to 0.07–0.12% (Karl Fischer, ASTM E203‑16), a level required for subsequent organometallic reactions that are sensitive to proton sources. Deviation from these crystallization parameters—for example, cooling below 0 °C—tended to co‑precipitate the cis‑diastereomer, raising the impurity level to 0.6–0.9% and lowering the batch acceptance rate.

When Scalable Synthesis Demands Orthogonal Stability in Multi‑Kilogram Campaigns

The tosyl protecting group has proven indispensable in sequences where other amine protections fail under the required reaction conditions. In published patent literature describing macrocyclic HCV NS3 protease inhibitors (WO 2009/010530 A1), the N‑tosylpyrrolidine‑2‑methanol intermediate survived a sequence of Suzuki cross‑coupling (Pd(PPh₃)₄, Na₂CO₃, DME/H₂O, 80 °C), ester saponification (LiOH, MeOH/H₂O, 25 °C), and macrolactamization (HATU, DIPEA, DMF, 0.01 M) without detectable cleavage, as monitored by LCMS (ESI⁺, extracted ion chromatogram for the des‑tosyl mass). The equivalent N‑Boc‑protected intermediate, when exposed to the macrolactamization conditions, underwent 23% ring‑opening via pyrrolinium ion formation, confirmed by the appearance of a new peak with a mass shift of +18 Da and a relative retention time of 1.32 by LCMS. This differential stability directly impacts the step count and purification burden in a GMP campaign: the tosyl route required a single silica plug filtration after the lactamization, whereas the Boc route necessitated a full column chromatography and a re‑protection step, adding 48 h to the production cycle and reducing overall yield by 14%. Moisture sensitivity of the tosyl group under reductive conditions imposes a strict pre‑drying requirement when scaling detosylation reactions. After storage at ambient relative humidity greater than 60%, the crystal lattice can incorporate 0.3–0.5% water, which quenches the sodium naphthalenide reagent and causes incomplete conversion. Redrying in a vacuum oven at 45 °C for 12 h restores water content below 0.1% and restores the detosylation conversion to >98%. Additionally, the product must not be stored in the presence of amine bases (e.g., triethylamine, DBU), as even trace quantities catalyze a slow β‑elimination across the C4 hydroxyl to form the ene‑sulfonamide, a degradation pathway detected by the appearance of a new signal at δ 5.82 ppm in ¹H NMR (CDCl₃). Standard storage in tightly sealed containers under argon at -20 °C prevents this decomposition over 24‑month stability windows, as demonstrated by accelerated stability studies at 40 °C/75% RH where the ene‑sulfonamide remained below 0.15% after 6 months.